<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39388648</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1665-1731</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Archivos de cardiologia de Mexico</Title><ISOAbbreviation>Arch Cardiol Mex</ISOAbbreviation></Journal><ArticleTitle>[Frequency of cutaneous drug reactions in the outpatient dermatology clinic at the National Institute of Cardiology Ignacio Ch&#xe1;vez over a ten-year period].</ArticleTitle><Pagination><StartPage>59</StartPage><EndPage>68</EndPage><MedlinePgn>59-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/ACM.24000107</ELocationID><Abstract><AbstractText>Cutaneous adverse drug reactions, or pharmacodermias, are the most common form of adverse drug reactions (ADR). It was our interest to know their epidemiological behavior in a tertiary hospital level in Mexico. We stablished the frequency of ADR in 61 infants and adults hospitalized patients and those seen in the outpatient Dermatology Clinic at the National Institute of Cardiology Ignacio Ch&#xe1;vez in Mexico City (INCICh) over a period of 10 years. The most frequently diagnosed pharmacodermias were acneiform dermatitis, cutaneous hyperpigmentation and maculopapular exanthema mainly associated to prednisone, hydroxychloroquine, cephalothin, amiodarone and vitamin B-complex, although we registered less frequently more severe and hazardous reactions. These results were consistent with other reports in our country. Multiple drugs administered at a time was an important causative factor for the ADR. It is necessary for every practitioner to develop skills that permit the identification of these dermatoses in order to correctly manage each case and diminish the morbimortality associated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coria-V&#xe1;zquez</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universidad Del Valle de M&#xe9;xico Campus Quer&#xe9;taro, Quer&#xe9;taro, Qro., M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz-L&#xf3;pez</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espino-Mier</LastName><ForeName>Katya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lara-Morales</LastName><ForeName>Sonia M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez-Vel&#xe1;zquez</LastName><ForeName>Mar&#xed;a F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacy-Niebla</LastName><ForeName>Rosa Ma</ForeName><Initials>RM</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Frecuencia de reacciones adversas cut&#xe1;neas a medicamentos en la consulta externa de dermatolog&#xed;a del Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, en un periodo de diez a&#xf1;os.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Arch Cardiol Mex</MedlineTA><NlmUniqueID>101126728</NlmUniqueID><ISSNLinking>1665-1731</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003875" MajorTopicYN="Y">Drug Eruptions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003880" MajorTopicYN="N">Dermatology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000554" MajorTopicYN="N">Ambulatory Care Facilities</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Las reacciones adversas cut&#xe1;neas a medicamentos o farmacodermias constituyen la forma m&#xe1;s com&#xfa;n de las reacciones adversas a medicamentos (RAM), por lo que fue nuestro inter&#xe9;s conocer su comportamiento epidemiol&#xf3;gico en un hospital de tercer nivel en M&#xe9;xico. Establecimos su frecuencia en 61 pacientes, infantes y adultos, hospitalizados y de la Consulta externa de Dermatolog&#xed;a en el Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez (INCICh) en la Ciudad de M&#xe9;xico, en 10 a&#xf1;os, y encontramos que la reacciones m&#xe1;s frecuentes fueron la dermatitis acneiforme, la hiperpigmentaci&#xf3;n cut&#xe1;nea y el exantema maculopapular principalmente asociados a prednisona, hidroxicloroquina, cefalotina, amiodarona y complejo B, aunque con menos frecuencia registramos reacciones m&#xe1;s graves, lo cual es consistente con otros reportes similares en nuestro pa&#xed;s. La polifarmacia de la mayor&#xed;a de los pacientes que presentaron estas RAM fue un factor determinante en su presentaci&#xf3;n. Es fundamental desarrollar habilidades para reconocer el cuadro cl&#xed;nico de estas dermatosis, con el fin de abordar correctamente cada caso y disminuir la morbimortalidad de las RAM.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse drug reaction</Keyword><Keyword MajorTopicYN="N">Cutaneous adverse drug reaction</Keyword><Keyword MajorTopicYN="N">Drugs</Keyword><Keyword MajorTopicYN="N">Pharmacodermia</Keyword></KeywordList><CoiStatement>Los autores declaran no tener conflicto de intereses.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>15</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>18</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>15</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39388648</ArticleId><ArticleId IdType="pmc">PMC12148515</ArticleId><ArticleId IdType="doi">10.24875/ACM.24000107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montan&#xe9; E, Santesmases J. Reacciones adversas a medicamentos. Rev Med Clin. 2020;154(5):178&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">31771857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kommu S, Carter C, Whitfield P.  Adverse drug reactions [Internet] Treasure Island (FL): StatPearls Publishing; 2024.  Disponible en: https://pubmed.ncbi.nlm.nih.gov/38261714 .</Citation><ArticleIdList><ArticleId IdType="pubmed">38261714</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora RV, Patel TB, Tandel JJ, Patel JK, Polra RV. Adverse cutaneous drug reactions at a rural-based tertiary health-care center in Gujarat:an eleven year study. Ind Derm online J. 2024;14(1):50&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9910533</ArticleId><ArticleId IdType="pubmed">36776185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L, Jin HB, Guan YY, Yang J. Pharmacovigilance of cutaneous adverse drug reactions in association with drugs and medical conditions:a retrospective study of hospitalized patients. BMC Pharmacol Toxicol. 2022;23(1):62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9364295</ArticleId><ArticleId IdType="pubmed">35948985</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AY. Immunological mechanisms in cutaneous adverse drug reactions. Biomol Ther (Seoul) 2024;32(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10762274</ArticleId><ArticleId IdType="pubmed">38148549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettuzzi T, Sanchez-Pena P, Lebrun-Vignes B. Cutaneous adverse drug reactions. Therapie. 2024;79(2):239&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">37980248</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Pozzo-Maga&#xf1;a BR, Liy-Wong C. Drugs and the skin:A concise review of cutaneous adverse drug reactions. Br J Clin Pharmacol. 2024;90(8):1838&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">35974692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockenhaupt M. Drug allergy and cutaneous adverse reactions. Handb Exp Pharmacol. 2022;268:195&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">34219202</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Aboud DM, Nessel TA, Hafsi W.  Adverse drug reactions [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Cutaneous Adverse Drug Reaction. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30422592 .</Citation><ArticleIdList><ArticleId IdType="pubmed">30422592</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez A, Rosales SP, Rangel S, Criollo E, Archer C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006;37(7):899&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez SA, Vega ME, Hojyo TMT. Epidemiolog&#xed;a de las reacciones adversas a f&#xe1;rmacos en el Servicio de Dermatolog&#xed;a del Hospital General Dr. Manuel Gea Gonz&#xe1;lez. Dermatol Rev Mex. 2011;55(6):327&#x2013;33.</Citation></Reference><Reference><Citation>Ch&#xe1;vez-Lemus FA, Reynoso-von Drateln C, Rodr&#xed;guez-Mart&#xed;nez N. Prevalencia de las farmacodermias en pacientes hospitalizados en el servicio de Dermatolog&#xed;a de la UMAE del Centro M&#xe9;dico Nacional de Occidente Periodo 2004-2012. Dermatol Rev Mex. 2014;58(4):339&#x2013;45.</Citation></Reference><Reference><Citation>Ralph E, Aronson JK. Adverse drug reactions:definitions, diagnosis and management. Lancet. 2000;356(9237):1255&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">11072960</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno LG, L&#xf3;pez BE, D&#xed;az EJ, Rodr&#xed;guez FL, Sol&#xed;s A. Caracter&#xed;sticas epidemiol&#xf3;gicas de farmacodermias en un hospital privado. Act Med. 2021;19(1):76&#x2013;80.</Citation></Reference><Reference><Citation>Arenas R. Dermatitis medicamentosas. In: Arenas R, editor. Dermatolog&#xed;a. Atlas, diagn&#xf3;stico y tratamiento. 7a edici&#xf3;n. Ciudad de M&#xe9;xico, M&#xe9;xico: McGraw-Hill; 2019. pp. 81&#x2013;89.</Citation></Reference><Reference><Citation>Su&#xe1;stegui I, Campos KI, Dom&#xed;nguez J, M&#xe9;ndez S. Reacciones cut&#xe1;neas adversas a medicamentos. Rev Med Inst Mex Seguro Soc. 2018;56(1):64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">29368897</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen CE, Jones JM. Recognition and management of severe cutaneous adverse drug reactions (including drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson Syndrome, and toxic epidermal necrolysis) Med Clin North Am. 2021;105(4):577&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">34059239</ArticleId></ArticleIdList></Reference><Reference><Citation>Tempark T, John S, Rerknimitr P, Satapornpong P, Sukasem C. Drug-induced severe cutaneous adverse reactions:insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics. Front Pharmacol. 2022;13:832048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9065683</ArticleId><ArticleId IdType="pubmed">35517811</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs M, Cardones A, Rahnama-Moghadam S. DRESS syndrome:clinical myths and pearls. Cutis. 2018;102(5):322&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30566546</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez B, Trejo N, Alfaro A, Rodr&#xed;guez R, Gonz&#xe1;lez D. Stevens-Johnson syndrome induced by paracetamol in a pediatric patient. Dermatol Rev Mex. 2021;65(6):991&#x2013;8.</Citation></Reference><Reference><Citation>Harbaoui S, Litaiem N.  Symmetrical drug-related intertriginous and flexural exanthema [Internet] Treasure Island (FL): StatPearls Publishing; 2022.  Disponible en: https://pubmed.ncbi.nlm.nih.gov/30969572 .</Citation><ArticleIdList><ArticleId IdType="pubmed">30969572</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair PA, Saleh HM, Salazar FJ.  Acneiform eruptions [Internet] Treasure Island (FL): StatPearls Publishing; 2024.  Disponible en: https://pubmed.ncbi.nlm.nih.gov/29083685 .</Citation><ArticleIdList><ArticleId IdType="pubmed">29083685</ArticleId></ArticleIdList></Reference><Reference><Citation>Dessinnioti C, Antoniou C, Katasambas A. Acneiform eruptions. Clin Dermatol. 2014;32(1):24&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24314375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahbouhi I, Aboudourib M, Hocar O, Amal S. Vitamin B12 induced acneiform eruption. Heliyon. 2023;9(5):e16120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10256894</ArticleId><ArticleId IdType="pubmed">37305488</ArticleId></ArticleIdList></Reference><Reference><Citation>Trejo JR, Gonz&#xe1;lez M, Figueroa E, Mar&#xed;n D. Granuloma anular diseminado. Rev Cent Dermatol Pascua. 2019;28(2):65&#x2013;70.</Citation></Reference><Reference><Citation>Gim&#xe9;nez R, Carrasco S. Drug-induced hyperpigmentation:review and case series. JABFM. 2019;34(4):628&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">31300585</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamri L. Hyperpigmentation induced by hydroxychloroquine. Dermatol Pract Concept. 2023;13(4):e2023235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10656153</ArticleId><ArticleId IdType="pubmed">37992335</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LC, Sanhueza M. Hiperpigmentaci&#xf3;n cut&#xe1;nea y melanoniquia provocada por hidroxicloroquina:primer caso reportado en Chile. Actas Dermosifiliogr. 2020;111(9):771&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32679121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardern-Jones MR, Mockenhaupt M. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol. 2019;19(4):283&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">31247634</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary R, Vinay K, Srivastava N, Bishnoi A, Kamat D, Parsad D, et al. Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome:A prospective case-control study. J Am Acad Dermatol. 2021;85:901&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33785387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori Sh, Hickey A, Dusza S W, Lacouture ME, Markova A. Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions. J Am Acad Dermatol. 2019;80:608&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372330</ArticleId><ArticleId IdType="pubmed">30612984</ArticleId></ArticleIdList></Reference><Reference><Citation>Irigoyen ML, Rojo MI, Meyer RH, Leyva I, Zendejas VM, Garc&#xed;a AD, et al. Pruebas modificadas de degranulaci&#xf3;n de bas&#xf3;filos y factor de inhibici&#xf3;n de migraci&#xf3;n de leucocitos en alergia a f&#xe1;rmacos. Estudio de 2009 a 2014 Rev Alerg Mex. 2016;63(4):342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">27795214</ArticleId></ArticleIdList></Reference><Reference><Citation>McNish AJS, Ho JD, East-Innis ADC. Severe cutaneous adverse reactions in a terciary care center in Jamaica. J Am Acad Dermatol. 2024;15:139&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10966286</ArticleId><ArticleId IdType="pubmed">38545494</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockenhaupt M. Drug allergy and cutaneous adverse reactions. Handb Exp Pharmacol. 2022;268:195&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">34219202</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfirevic A, Pirmohamed M, Marinovic B, Harcourt-Smith L, Jorgensen AL, Cooper TE. Genetic testing for prevention of severe drug-induced skin rash. Cochrane Database Syst Rev. 2019;7(7):CD010891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6636675</ArticleId><ArticleId IdType="pubmed">31314143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroshinsky D. Adverse cutaneous reactions to medications. Clin Dermatol. 2019;38(6):605&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33341194</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelincik A, Cavkaytar O, Kuyucu S. An update on the management of severe cutaneous drug hypersensitivity reactions. Curr Pharm Des. 2019;25(36):3881&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">31692425</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung Sh-I, Mockenhaupt M, Blimenthal KG, Abe R, Ueta M, Ingen-Housz-Oro S, et al. Severe cutaneous adverse reactions. Nat Rev Dis Primers. 2024;10:30.</Citation><ArticleIdList><ArticleId IdType="pubmed">38664435</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25727841</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1668-3501</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archivos argentinos de pediatria</Title><ISOAbbreviation>Arch Argent Pediatr</ISOAbbreviation></Journal><ArticleTitle>[Ornithine carbamoyltransferase deficiency. A clinical case].</ArticleTitle><Pagination><StartPage>e94</StartPage><EndPage>e97</EndPage><MedlinePgn>e94-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5546/aap.2015.e94</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0325-00752015000200017</ELocationID><Abstract><AbstractText>Disorders of urea cycle account for up to 60% of severe neonatal hyperamoniemias. The base of this cycle disorders results in a deficit of its enzymes. Deficiency of the enzyme ornithine transcarbamylase is the most frequently detected. The prognosis depends on the degree of enzyme deficiency, age, early diagnosis and initiation of treatment. We report the case of a teenager who was treated with prednisone because of a peripheral facial palsy. He showed a progressive worsening and died a few days later. The high levels of ammonia made suspect a congenital disorder of urea cycle. The postmortem genetic study confirmed it. We studied the family and advised carriers. We reflect about the importance of the neonatal screening programs and their applicability for detection of inborn errors of metabolism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herr&#xe1;iz Gastesi</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Consulta de Gastroenterologia Infantil, Hospital Cl&#xed;nico Universitario Lozano Blesa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez</LastName><ForeName>Oscar Esteban</ForeName><Initials>OE</Initials><AffiliationInfo><Affiliation>Consulta de Gastroenterologia Infantil, Hospital Cl&#xed;nico Universitario Lozano Blesa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco P&#xe9;rez-Aramend&#xed;a</LastName><ForeName>Mar&#xed;a Jes&#xfa;s</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Consulta de Gastroenterologia Infantil, Hospital Cl&#xed;nico Universitario Lozano Blesa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez Raposo-Piedrafita</LastName><ForeName>Mar&#xed;a Carmen</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Consulta de Gastroenterologia Infantil, Hospital Cl&#xed;nico Universitario Lozano Blesa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cebollada Gracia</LastName><ForeName>Ana Delia</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Consulta de Gastroenterologia Infantil, Hospital Cl&#xed;nico Universitario Lozano Blesa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloris Moraleja</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Consulta de Gastroenterologia Infantil, Hospital Cl&#xed;nico Universitario Lozano Blesa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>D&#xe9;ficit de ornitina transcarbamilasa. Caso cl&#xed;nico.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Arch Argent Pediatr</MedlineTA><NlmUniqueID>0372460</NlmUniqueID><ISSNLinking>0325-0075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020163" MajorTopicYN="Y">Ornithine Carbamoyltransferase Deficiency Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25727841</ArticleId><ArticleId IdType="doi">10.5546/aap.2015.e94</ArticleId><ArticleId IdType="pii">S0325-00752015000200017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">9268107</PMID><DateCompleted><Year>1997</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0148-7299</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>3</Issue><PubDate><Year>1997</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>American journal of medical genetics</Title><ISOAbbreviation>Am J Med Genet</ISOAbbreviation></Journal><ArticleTitle>Progressive diaphyseal dysplasia: a three-generation family with markedly variable expressivity.</ArticleTitle><Pagination><StartPage>348</StartPage><EndPage>352</EndPage><MedlinePgn>348-52</MedlinePgn></Pagination><Abstract><AbstractText>Progressive diaphyseal dysplasia was found in a 3-generation family including 18 affected individuals. We describe the clinical and radiographic manifestations in 6 of 18 patients with this autosomal-dominant bone dysplasia and the good symptomatic response to corticosteroid treatment in one of these. The variability of manifestations of the disease in this family and in others previously described seems to depend on the sex of the patient and the parental origin of the mutation. The patients with more severe symptoms are males who inherited an allele of paternal origin. We suggest that the progressive diaphyseal dysplasia gene has a function in endochondral bone formation and that its mutation is a dynamic one with repeat expansion enhanced in father-to-son transmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saraiva</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Consulta de Gen&#xe9;tica, Hospital Pedi&#xe1;trico de Coimbra, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet</MedlineTA><NlmUniqueID>7708900</NlmUniqueID><ISSNLinking>0148-7299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003966" MajorTopicYN="N">Camurati-Engelmann Syndrome</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018392" MajorTopicYN="N">Genomic Imprinting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018895" MajorTopicYN="N">Microsatellite Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9268107</ArticleId><ArticleId IdType="doi">10.1002/(sici)1096-8628(19970822)71:3&lt;348::aid-ajmg17&gt;3.0.co;2-k</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1096-8628(19970822)71:3&lt;348::AID-AJMG17&gt;3.0.CO;2-K</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>